Discontinued — last reported Q3 '22
Deere & Company Acquisitions remained flat by 0.0% to $25.25M in Q4 2025 compared to the prior quarter. Over 2 years (FY 2021 to FY 2023), Acquisitions shows an upward trend with a 41.9% CAGR.
High spending indicates an aggressive growth strategy, while low spending may indicate a focus on organic growth or debt reduction.
This represents the net cash outflow for the purchase of other businesses or strategic assets, adjusted for any cash acq...
Highly variable; pharmaceutical companies frequently use M&A to offset patent cliffs and expand therapeutic portfolios.
cf_acquisitions| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $225.00M | $24.00M | $449.00M | $15.00M | $10.00M | $20.50M | $20.50M | $20.50M | $20.50M | $25.25M | $25.25M | $25.25M | $25.25M |
| QoQ Change | — | — | — | -89.3% | >999% | -96.7% | -33.3% | +105.0% | +0.0% | +0.0% | +0.0% | +23.2% | +0.0% | +0.0% | +0.0% |
| YoY Change | — | — | — | — | — | — | -95.6% | -14.6% | -95.4% | +36.7% | +105.0% | — | — | — | — |
We use cookies for analytics. See our Privacy and Cookie Policy.